**Breaking News** Reports 14x YOY Increase in Revenue

There are plenty of reasons why this growing biotech company should be on your watchlist, including an $18.70 price target! ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ Unsubscribe

There are plenty of reasons why this growing biotech company should be on your watchlist, including an $18.70 price target! The biotech space is anticipated for a big rebound this year and one company that looks well-positioned to stand out is BioStem Technologies, Inc. (OTCQB: BSEM). In the last year, the company’s share price has moved from around $1 to over $9. It’s evident that Wall Street is paying attention to this biotech company’s game-changing offerings for the global wound care market. The company is making waves for its focus on harnessing elements of perinatal tissue derived from the human placenta for manufacturing structural tissue allografts to heal wounds. The market for improved wound care products is growing exponentially. In terms of revenue, the global wound care market in terms of revenue was estimated to be worth $20.8 billion in 2022 and is poised to reach $27.2 billion by 2027, growing at a CAGR of 5.4% from 2022 to 2027. It wasn’t that long ago that Zack’s Small Cap Research had increased its price target on the stock, given the explosive Q3 earnings that were reported and recently reiterated that the company may be undervalued! Zack’s has increased its price target to $18.70! The price increase comes shortly after the company released some preliminary and unaudited numbers that showed net revenue for 4Q2023 of $11.5 million, well ahead of Zack’s estimates and a more than 1300% increase from the year ago period! For the year, the company also showed preliminary net revenue of $16.7 million, which would be more than a 140% increase over 2022. The official release and the full financials, according to the company, will be released in March. See how the evidence is pointing to BioStem being one of the most exciting biotech companies under followed on Wall Street!

Thank you for subscribing to Insider Trades Daily, which covers the most recent insider buying and selling activity from Wall Street CEO's, CFO's, COO's and other insiders.   This message is a paid advertisement sent on behalf of Huge Alerts, a third-party advertiser of InsiderTrades.com and MarketBeat.     This message is a paid advertisement for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency and Huge Alerts. American Consumer News, LLC dba MarketBeat receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $5,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Sideways Frequency or Huge Alerts. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts' website for additional information about the relationship between Huge Alerts and BioStem Technologies Inc. (OTC: BSEM).     If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.   If you no longer wish to receive email from InsiderTrades.com, you can unsubscribe.   © 2006-2024 MarketBeat Media, LLC. 345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.   Today's Bonus Content: Discover Why Smart Conservatives Are Turning to Gold (Click to Opt-in)